secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001689548-23-000157
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Q3 net loss $24.6M; starts Essential3 Phase 3 for ulixacaltamide
-----------------------------------------------------------------------

- Cash $101.1M as of Sep 30, 2023, providing runway into Q1 2025.
- Initiated Essential3 Phase 3 program for ulixacaltamide in essential tremor; enrollment expected H1 2024.
- Completed Part 1 dosing of EMBRAVE study for elsunersen in SCN2A-DEE; seeking FDA guidance.
- R&D expenses $17.3M (down from $30.4M YoY); net loss $24.6M (down from $43.9M YoY).
- Expects topline results from PRAX-628 Phase 2a PPR study in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/0001689548-23-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000157/prax-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001689548-23-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer